|
Action Tremor
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Amblyopia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Anxiety
|
0.010 |
Biomarker
|
disease |
BEFREE |
Exploratory efficacy measures included dimensional anxiety scales (Pediatric Anxiety Rating Scale [PARS] and Screen for Child Anxiety Related Emotional Disorders [SCARED]), as well as the Clinical Global Impression-Improvement (CGI-I) scale.
|
28165762 |
2017 |
|
Anxiety Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Exploratory efficacy measures included dimensional anxiety scales (Pediatric Anxiety Rating Scale [PARS] and Screen for Child Anxiety Related Emotional Disorders [SCARED]), as well as the Clinical Global Impression-Improvement (CGI-I) scale.
|
28165762 |
2017 |
|
Arteriosclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Genetic polymorphism of apolipoprotein A-IV in five different regions of Europe. Relations to plasma lipoproteins and to history of myocardial infarction: the EARS study. European Atherosclerosis Research Study.
|
7980697 |
1994 |
|
Arteriosclerosis
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Effect of variation in the apo A-IV gene on body mass index and fasting and postprandial lipids in the European Atherosclerosis Research Study II. EARS Group.
|
9925658 |
1999 |
|
Arteriosclerosis
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Students with and without paternal history of myocardial infarction (cases and control subjects [controls]) were studied in the European Atherosclerosis Research Studies I and II (EARS-I and -II).
|
9264476 |
1997 |
|
Arteriosclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIC and PAI-1 in European offspring--the EARS study. European Atherosclerosis Research Study Group.
|
8052959 |
1994 |
|
Arteriosclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Apo(a) phenotypes and Lp(a) concentrations in offspring of men with and without myocardial infarction. The EARS Study. European Atherosclerosis Research Study.
|
7627688 |
1995 |
|
Ataxia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Atherosclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Genetic polymorphism of apolipoprotein A-IV in five different regions of Europe. Relations to plasma lipoproteins and to history of myocardial infarction: the EARS study. European Atherosclerosis Research Study.
|
7980697 |
1994 |
|
Atherosclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Apo(a) phenotypes and Lp(a) concentrations in offspring of men with and without myocardial infarction. The EARS Study. European Atherosclerosis Research Study.
|
7627688 |
1995 |
|
Atherosclerosis
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Effect of variation in the apo A-IV gene on body mass index and fasting and postprandial lipids in the European Atherosclerosis Research Study II. EARS Group.
|
9925658 |
1999 |
|
Atherosclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIC and PAI-1 in European offspring--the EARS study. European Atherosclerosis Research Study Group.
|
8052959 |
1994 |
|
Atherosclerosis
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Students with and without paternal history of myocardial infarction (cases and control subjects [controls]) were studied in the European Atherosclerosis Research Studies I and II (EARS-I and -II).
|
9264476 |
1997 |
|
Athetosis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Several studies have suggested a role for the glutamyl prolyl tRNA synthetase (EPRS) in breast cancers, although none has identified any underlying mechanism about how EPRS contributes to carcinogenesis.
|
27612429 |
2016 |
|
Cardiovascular Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
In conclusion, the PARS risk assessment chart is a simple, accurate, and well-calibrated tool for predicting a 10-year risk of CVD occurrence in Iranian population and can be used in an attempt to develop national guidelines for the CVD management.
|
29261727 |
2017 |
|
Cardiovascular Diseases
|
0.030 |
GeneticVariation
|
group |
BEFREE |
As a part of the EARS study we assessed the role of the common apo A-IV polymorphism in determining the hereditary predisposition to cardiovascular disease.
|
7980697 |
1994 |
|
Cardiovascular Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Correction: PARS risk charts: A 10-year study of risk assessment for cardiovascular diseases in Eastern Mediterranean Region.
|
29370204 |
2018 |
|
Cerebral atrophy
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Chikungunya Fever
|
0.010 |
Biomarker
|
disease |
BEFREE |
Due to the increasing likelihood of co-circulation and co-infection with viruses, we aimed to identify a pharmacologically targetable host factor that can inhibit multiple viruses and show that a potent antagonist of prolyl tRNA synthetase (halofuginone) suppresses both Chikungunya and Dengue viruses.
|
30521835 |
2019 |
|
Coccidiosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeting Prolyl-tRNA Synthetase to Accelerate Drug Discovery against Malaria, Leishmaniasis, Toxoplasmosis, Cryptosporidiosis, and Coccidiosis.
|
28867614 |
2017 |
|
Coinfection
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Due to the increasing likelihood of co-circulation and co-infection with viruses, we aimed to identify a pharmacologically targetable host factor that can inhibit multiple viruses and show that a potent antagonist of prolyl tRNA synthetase (halofuginone) suppresses both Chikungunya and Dengue viruses.
|
30521835 |
2019 |
|
Congenital heart disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Eight core ARSs (EPRS, MRS, QRS, RRS, IRS, LRS, KRS, DRS) combined with three nonenzymatic components form a complex known as multisynthetase complex (MSC).We hypothesize that the single-nucleotide polymorphisms (SNPs) of the eight core ARS coding genes might influence the susceptibility of sporadic congenital heart disease (CHD).
|
25310850 |
2014 |